PCSK9 Inhibitor Evolocumab Continues to Lack Cost-Effectiveness
Findings for addition of evolocumab to standard tx in atherosclerotic cardiovascular disease
Atherosclerosis
Greater CV Benefit With Rivaroxaban Plus Aspirin vs Monotherapy in Stable ASCVD
Despite more major bleeding events, rivaroxaban plus aspirin therapy had a greater cardiovascular benefit in patients with stable atherosclerotic vascular disease vs monotherapy.
Role of Race and Ethnicity in Cardiovascular Health
Experts weigh in on how to improve racial and ethnic disparities in cardiovascular health.
Measuring Visceral Adipose Tissue With DXA to Predict Atherosclerotic CVD
Fourteen percent of study participants experienced incident athersclerotic cardiovascular disease events.
Gray Hair Predictive of Coronary Artery Disease in Men
Hair whitening score, hypertension, and dyslipidemia were all independent predictors of atherosclerotic coronary artery disease.
FOURIER Trial Data Questions: Are PCSK9 Inhibitors The Right Choice?
Results of the FOURIER trial, presented at the 2017 ACC Scientific Sessions, raise questions about the efficacy of PCSK9 inhibitors as long-term therapy for patients with atherosclerotic CVD.
Patient-Clinician Communication Key in Managing Heart Disease Treatment
Two studies examined the positive outcomes of clear patient-clinician communication on management and treatment of heart disease.
Novel Multimodality Testing Strategy Improves CVD Risk Assessment
A mutlimodal strategy combines 5 separate tests to significantly improve CVD and ASVCD risk assessment.
Statin Eligibility Requirements In African Americans With Atherosclerosis
According to ACC/AHA Guidelines presented at ACC 2017, targeted imaging should be used to personalize statin recommendation programs.
LDL-C Lowered Below Current Targets Beneficial to Atherosclerotic CVD
Evolocumab reduced LDL-C levels by 59% and lowered the risk of CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization by 15%.
- Loading...
Loading...
Next post in ACC 2017 Meeting Highlights
Loading... 
Loading...